If you have spent any time reading about epithalon (also spelled epitalon), you have met the number: a 28% reduction in deaths over 12 years in elderly patients. It is the single most persuasive-sounding human figure in the entire pineal peptide literature, and it gets copied into product pages, forum posts and "epithalon research" explainers almost verbatim. There is just one problem with using it to describe epithalon: the compound in that trial wasn't epithalon.

This post is a myth-versus-evidence breakdown of where that mortality claim actually comes from, why the distinction between two similarly named substances matters, and what the honest state of the human evidence looks like in 2026 — including for readers asking whether epithalon is legal in Australia.

What is epithalon, and what is Epithalamin?

These are two different things, and almost every overstated claim about epithalon traces back to blurring them.

Epithalamin is a crude polypeptide extract of bovine pineal glands, developed in the Soviet Union and used in the Russian-language clinical work from the 1970s onwards. It is a biological preparation of undefined composition — a mixture, not a molecule.

Epithalon (epitalon, AEDG) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — designed on the basis of the amino acid composition of that extract and identified as its putative active fragment (Wikipedia summary of the chemistry; see also the 2025 IJMS overview of epitalon). It is a defined, four-amino-acid compound that can be made by peptide synthesis.

"Designed from" is not "equivalent to". A crude glandular extract can contain dozens of peptides, hormones and contaminants, any of which might drive an outcome. Assuming the tetrapeptide carries the extract's clinical effects is a hypothesis, not a finding — and it is not a hypothesis that has been tested head-to-head in humans.

Where the 28% figure actually comes from

The number traces to a paper by O. V. Korkushko, V. Kh. Khavinson and colleagues (Institute of Gerontology, Kyiv, and the St Petersburg Institute of Bioregulation and Gerontology), published in Bulletin of Experimental Biology and Medicine in 2006: Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging.

The reported design was a 12-year randomised study in elderly patients with coronary disease and accelerated cardiovascular ageing, all on the same background therapy. The reported results: 28% fewer deaths in the treated group, cardiovascular mortality around two-fold lower, and reduced "functional age" with improved exercise tolerance.

Read the title again. The agent is epithalamine — the bovine pineal preparation. Not the synthetic tetrapeptide. Every time that 28% is presented as an epithalon result, a crude animal-derived extract has been quietly swapped for a synthetic peptide.

The other problems with leaning on it

Even taken entirely at face value as an Epithalamin result, this is thin ground:

  • One group, one region. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality reviewers noted that the bulk of epithalamin/epithalon research has been conducted in Russia and has not been subject to independent confirmation, and that of roughly 110 published articles, at least half are in Russian with no English translation available — meaning they could not be assessed at all (ADDF Cognitive Vitality review).
  • Reporting standards. These papers predate modern trial-reporting norms. There is no registered protocol, no published statistical analysis plan, no independent data monitoring, and no adjudicated cause-of-death committee of the kind a Western regulator would expect for a mortality endpoint.
  • Never rerun. In the two decades since, nobody outside that research lineage has attempted a replication of the mortality finding. Not a failed replication — simply no replication.

What the strongest epithalon evidence actually shows

The best-quality work specifically on the tetrapeptide is not clinical at all. In September 2025, a group at Brunel University London (with Royal Brompton Hospital co-authors) published the first genuinely independent human-cell test of the telomere claim in Biogerontology, reporting dose-dependent telomere lengthening in normal mammary epithelial cells and fibroblasts alongside increased hTERT expression and telomerase activity (open-access paper).

That is a meaningful result — and it is a result in cells in a dish. It says nothing about lifespan, mortality or "biological age" in a person. The same paper also reported telomere lengthening in breast cancer cell lines, apparently via the ALT pathway, which is an open question rather than a reassurance. The paper subsequently carried a published correction.

So the honest summary is uncomfortable for both camps: the mechanism has now been independently observed in human cells, and the human outcome data remains a single unreplicated cohort on a different substance. Our full profile at /peptides/epithalon tracks both threads as they develop.

Is epithalon legal in Australia? The regulatory reality

Epithalon is approved nowhere in the world as a medicine — not by the TGA, not by the FDA, not by the EMA. There is no epithalon product on the Australian Register of Therapeutic Goods, which means no Australian regulator has assessed its quality, safety or efficacy for any use. Epithalamin, the bovine extract behind the 28% figure, has never been an approved medicine in Australia either.

"Not approved" is not the same as "unregulated". The TGA has issued standing warnings about the risks of importing unapproved peptide products marketed online, citing unverified quality, unknown contents and the absence of any efficacy assessment (TGA safety alert). Supplying or advertising an unapproved therapeutic good in Australia sits inside the Therapeutic Goods Act regardless of how a product is labelled. We don't tell readers where to buy anything — see the rest of our peptides section for the same treatment applied to other compounds.

How to read any epithalon claim from here

A simple three-question filter catches most of the overreach:

  1. Which substance? Epithalamin (bovine extract) or epithalon (synthetic AEDG)? If a source doesn't say, treat the claim as unsourced.
  2. Which system? Cells, rodents, or people? Telomerase upregulation in a dish is not a clinical outcome.
  3. Who ran it? If the answer is the same research lineage that generated the original claim, replication is still outstanding.

Want these breakdowns as they're published? Join the free updates list.

FAQ

Did epithalon reduce deaths by 28% in a clinical trial?

No. The 28% figure comes from a 2006 Russian/Ukrainian paper on Epithalamin, a crude bovine pineal gland extract, not the synthetic tetrapeptide epithalon. It has never been independently replicated, and no mortality trial of epithalon itself has been published.

What is the difference between epithalon and Epithalamin?

Epithalamin is an undefined polypeptide extract from bovine pineal glands; epithalon (epitalon, AEDG) is a synthetic four-amino-acid peptide designed from that extract's amino acid composition. They are not interchangeable, and most dramatic human claims belong to the extract.

Is epithalon legal in Australia?

Epithalon is not approved as a medicine anywhere, including by the TGA, and no epithalon product appears on the ARTG. The TGA has warned specifically about the risks of importing unapproved peptide products promoted online.

Is there any good human evidence for epithalon?

Not yet. The strongest independent work to date is the 2025 Brunel University London study in human cell lines, not people. There are no adequately powered, registered, placebo-controlled human trials of epithalon.

Sources

Not medical advice. Epithalon is an investigational compound not approved as a medicine by the TGA or any other regulator; retatrutide.net.au is independent and does not sell or source peptides.